Panitumumab (Vectibix)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: EGFR antagonist; recombinant human IgG2 kappa monoclonal antibody that binds to EGFR (human epidermal growth factor receptor), competitively inhibiting binding of epidermal growth factor (EGF). EGFR is overexpressed in certain cancers, such as colon & rectal cancer, and plays a role in the signal transduction pathways that lead to transcription of genes that promote cell growth, survival, and motility. Blocking EGFR in a population overexpressing EGFR has been observed to inhibit cell growth and induce apoptosis.[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

History of changes in EMA indication

  • 2007-12-03: Initial authorization

History of changes in Health Canada indication

  • 2008-04-03: Initial notice of compliance with conditions
  • 2015-02-19: Conditions were met

History of changes in PMDA indication

  • 2010-04-16: Initial approval for the treatment of unresectable, advanced or recurrent colorectal cancer with wild-type KRAS.

Also known as

  • Generic names: ABX-EGF, clone E7.6.3
  • Brand name: Vectibix